BACKGROUND Neoadjuvant therapies induce tumor regression,resulting in improved surgical resection and pathologic complete response rates,as well as long-term diseasefree and overall survival(OS).In addition to the tum...BACKGROUND Neoadjuvant therapies induce tumor regression,resulting in improved surgical resection and pathologic complete response rates,as well as long-term diseasefree and overall survival(OS).In addition to the tumor regression score,serum inflammatory markers,including neutrophil,lymphocyte,platelet,and serum albumin levels,are used to determine prognosis.AIM To investigate the effect of histological features and serum inflammatory markers on the prognosis of gastric cancer following neoadjuvant treatment.METHODS Neutrophil-to-lymphocyte ratio(NLR),platelet-to-lymphocyte ratio(PLR),and serum albumin levels were retrospectively recorded for 177 patients receiving neoadjuvant 5-fluorouracil,leucovorin,oxaliplatin and docetaxel chemotherapy.Disease-free and OS were analyzed based on tumor histopathological features,type of surgery,regression scores,and serum inflammatory markers.RESULTS Patients over 65 years of age,those with lymphovascular or perineural invasion,hypoalbuminemia,and those who did not receive adjuvant therapy were found to be at higher risk for shorter recurrence/relapse intervals[hazard ratio(HR):1.64,P=0.04;HR:4.20,P<0.001;HR:1.87,P=0.03;HR:3.5,P<0.001;and HR:2.73,P=0.01,respectively].Lymphovascular invasion,R1 resection,lack of adjuvant treatment,and hypoalbuminemia negatively influenced OS(HR:3.68,P<0.003;HR:2.37,P=0.01;HR:3.99,P<0.001;and HR:2.50,P=0.01,respectively).No effect of NLR and PLR was observed.CONCLUSION Current neoadjuvant therapies prolong disease-free and OS.The practical application of serum inflammatory markers(NLR and PLR)is limited due to the lack of standard cut-off values.Nutritional status,hypoalbuminemia,and incomplete perioperative chemotherapy have been associated with poor prognosis.展开更多
文摘BACKGROUND Neoadjuvant therapies induce tumor regression,resulting in improved surgical resection and pathologic complete response rates,as well as long-term diseasefree and overall survival(OS).In addition to the tumor regression score,serum inflammatory markers,including neutrophil,lymphocyte,platelet,and serum albumin levels,are used to determine prognosis.AIM To investigate the effect of histological features and serum inflammatory markers on the prognosis of gastric cancer following neoadjuvant treatment.METHODS Neutrophil-to-lymphocyte ratio(NLR),platelet-to-lymphocyte ratio(PLR),and serum albumin levels were retrospectively recorded for 177 patients receiving neoadjuvant 5-fluorouracil,leucovorin,oxaliplatin and docetaxel chemotherapy.Disease-free and OS were analyzed based on tumor histopathological features,type of surgery,regression scores,and serum inflammatory markers.RESULTS Patients over 65 years of age,those with lymphovascular or perineural invasion,hypoalbuminemia,and those who did not receive adjuvant therapy were found to be at higher risk for shorter recurrence/relapse intervals[hazard ratio(HR):1.64,P=0.04;HR:4.20,P<0.001;HR:1.87,P=0.03;HR:3.5,P<0.001;and HR:2.73,P=0.01,respectively].Lymphovascular invasion,R1 resection,lack of adjuvant treatment,and hypoalbuminemia negatively influenced OS(HR:3.68,P<0.003;HR:2.37,P=0.01;HR:3.99,P<0.001;and HR:2.50,P=0.01,respectively).No effect of NLR and PLR was observed.CONCLUSION Current neoadjuvant therapies prolong disease-free and OS.The practical application of serum inflammatory markers(NLR and PLR)is limited due to the lack of standard cut-off values.Nutritional status,hypoalbuminemia,and incomplete perioperative chemotherapy have been associated with poor prognosis.
